Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Gleevec
Pharma
Takeda's Iclusig tops Novartis' Gleevec decisively in Ph+ALL
At the ASCO virtual conference, Takeda touted data indicating Iclusig has the potential to become the “standard of care” in Ph+ALL.
Kevin Dunleavy
Feb 14, 2023 5:00pm
In Ph+ALL trial, Takeda's Iclusig outdoes Novartis' Gleevec
Nov 17, 2022 10:27am
ASCO: Novartis eyes full nod for Gleevec follow-on Scemblix
May 26, 2022 5:00pm
Deciphera cracks the door open for off-label cancer drug use
Jan 25, 2022 12:02pm
Novartis wins CML nod for new Gleevec follow-on Scemblix
Nov 1, 2021 6:51am
Novartis prevails against pair of Gleevec antitrust lawsuits
Aug 22, 2018 11:01am